AbbVie Inc. (0QCV.L)
| Previous close | 147.37 |
| Open | 150.11 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 146.93 - 147.40 |
| 52-week range | 146.93 - 147.40 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 2.191B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 0.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Abbvie stock falls amid growing biosimilar competition
Pharmaceutical giant AbbVie Inc. (ABBV) shares came under pressure as the market closed on Friday, following the disappointing first quarter sales performance of the company's arthritis drug, Humira. The company forecast that Humira's sales could slow further in the face of heightened competition. Yahoo Finance's health reporter Anjalee Khemlani breaks down the details, providing insight into the rise of biosimilars in the market. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith
- Fool.co.uk
3 top US dividend stocks for value investors to consider in 2024
I’m searching far and wide to find the best dividend stocks that money can buy. Do the Americans have more to offer when it comes to value investing? The post 3 top US dividend stocks for value investors to consider in 2024 appeared first on The Motley Fool UK.
- Yahoo Finance Video
AbbVie stock higher on strong Q4 earnings, 2024 guidance
Pharmaceutical firm AbbVie (ABBV) stock ticks up on strong fourth-quarter earnings results, beating Wall Street estimates and issuing just as strong 2024 guidance. Yahoo Finance takes a closer look at AbbVie's figures and if its botox products can catch on as much as recent GLP-1 weight loss drugs. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
